Physician profile
Adam Milman
NPI 1912021262
$2,434.23
in general payments reported to CMS, 2019-2025
25 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $46.44 · 2021: $86.74 · 2022: $182 · 2023: $356 · 2024: $1,086 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $470.12 | 2024 | |
| Abbvie INC. | $352.78 | 2022-2025 | |
| Abbott Laboratories | $336.79 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $240.08 | 2022-2025 | |
| Novo Nordisk INC | $162.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.67 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $138.91 | 2019 | |
| Astellas Pharma US INC | $101.67 | 2019-2025 | Veozah |
| Amgen INC. | $97.54 | 2019-2024 | Otezla, Repatha, Krystexxa |
| Dexcom, INC. | $41.26 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $41.04 | 2021-2023 | Arexvy, Shingrix |
| Avadel Cns Pharmaceuticals, LLC | $40.21 | 2024-2025 | Lumryz |
| Astrazeneca Pharmaceuticals Lp | $39.46 | 2021-2022 | |
| Lilly USA, LLC | $26.22 | 2020-2024 | Mounjaro, Zepbound |
| Baxter Healthcare | $25.10 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $22.50 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.23 | 2021 | |
| Medtronic, INC. | $19.88 | 2022 | |
| Inspire Medical Systems, INC. | $17.39 | 2025 | Inspire |
| Ethicon US, LLC | $17.27 | 2019 | |
| Hologic Sales and Service, LLC | $17.16 | 2025 | Aptima |
| Sunovion Pharmaceuticals INC. | $16.64 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2019 | |
| Merck Sharp & Dohme LLC | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Milman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.